News & Publications

Press Releases

February 06, 2026

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

September 04, 2025 

Pulmovant receives orphan drug designation in Japan for Mosliciguat for the treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

June 16, 2025 

Pulmovant announces publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

September 10, 2024 

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

Publications

July 23, 2026

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

September 28, 2025

2025 European Respiratory Society Congress Poster - PHocus: A Global Phase 2 Study of Inhaled Mosliciguat in Interstitial Lung Disease-Associated Pulmonary Hypertension (ILD-PH)

May 22, 2025

Clinical Pharmacokinetics: Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat

May 19, 2025

2025 American Thoracic Society Congress Presentation - ATMOS, a Proof-of-Concept Trial of Inhaled Mosliciguat in Untreated PAH or CTEPH

May 18, 2025

2025 American Thoracic Society Congress Poster - Characterizing Subgroup Variability within WHO Group 3 Pulmonary Hypertension with Real World Evidence 

September 10, 2024

2024 European Respiratory Society Congress Poster - ATMOS, a Proof-of-Concept Trial of Inhaled Mosliciguat in Untreated PAH or CTEPH